A wide range of bioactive indane based scaffolds are employed clinically as treatment of many disease states, including inflammatory [1], cancer [2] and neurological conditions [3] and also in the treatment of HIV [4]. Several classes of diastereoisomeric and enantiomeric molecules containing the indane moiety have been developed and characterised by our group [5-10]. Smooth muscle relaxation and mediator release inhibition properties have been demonstrated for many of these novel compounds [14-16]. This project is focussed on the design, synthesis and biological evaluation of novel drug-hybrids which combine anti-inflammatory and anti-tumour activities to target the interface between inflammatory disease and cancer. The first stage of this project will be involved with molecule making (organic/medicinal chemistry), structure characterisation and purity analysis, etc. In the second stage, the binding affinity of the compounds with the selected molecular targets will be examined (computational technique). Following the positive hits from the in-silico screening, the in-vitro bioactivity evaluation of these compounds will be investigated.
1. Bai H, Chen X, Zhang L, Dou X (2012) The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis. BMC Gastroenterol 12: 115.
2. Prakasham AP, Saxena AK, Luqman S, Chanda D, Kaur T, et al. (2012) Synthesis and anticancer activity of 2-benzylidene indanones through inhibiting tubulin polymerization. Bioorg Med Chem 20: 3049-3057.
3. Luan F, Cordeiro MNDS, Alonso N, García-Mera X, Caamaño O, et al. (2013) Tops-mode model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases. Bioorg Med Chem 21: 1870-1879.
4. Melillo B, Liang S, Park J, Schön A, Courter JR, et al. (2016) Small-molecule cd4-mimics: Structure-based optimization of hiv-1 entry inhibition. ACS Med Chem Lett 7: 330-334.
5. Zhang T, McCabe T, Marzec B, Frankish N, Sheridan H (2012) N-cyclo-pentyl-N-(3-oxo-2,3-dihydro-1H-inden-1-yl) acetamide. Acta Cryst E: 1600-5368.
6. Zhang T, Paluch K, Scalabrino G, Frankish N, Healy A-M, et al. (2015) Molecular structure studies of (1S,2S)-2-benzyl-2,3-dihydro-2-(1H-inden-2-yl)-1H-inden-1-ol. J Mol Struct 1083: 286-299.
7. Zhang, T., Scalabrino, G., Frankish, N. and Sheridan, H. (2018). Bioactive indanes: comparative in vitro metabolism study of PH46A, a new potential anti-inflammatory agent and biosynthesis of its primary metabolite PH132. Drug Metabolism & Toxicology, 9, 1-14.
8. Zhang, T., Scalabrino, G., Frankish, N. and Sheridan, H. (2018). Bioactive indanes: Proof of concept study for enantioselective synthetic routes to PH46A, a new potential anti-inflammation agent. Molecules, 23, 1-18.
9. Chan, K., Frankish, N., Zhang, T., Ece, A., Cannon, A., O'sullivan, J. and Sheridan, H. (2020). Bioactive indanes: insight into the bioactivity of indane dimers related to the lead anti‐inflammatory molecule PH46A. Journal of Pharmacy and Pharmacology.
10. Zhang, T., Scalabrino, G., Frankish, N. and Sheridan, H. (2020). Bioactive indanes: development and validation of an LC-MS/MS bioanalytical method for the determination of PH46A, a new potential anti-inflammatory agent, in dog and rat plasma and its application to a pharmacokinetic study in dog. Journal of Pharmaceutical and Biomedical Analysis, 179, 1-10.
Student requirements for this project
A min. 2.1 (Hons) BSc in BSc in Medicinal Chemistry, Biological Sciences or related disciplines.
If you are interested in submitting an application for this project, please complete an expression of interest formhttps://forms.office.com/r/wzGYFFKu1t
Continue with Facebook